IRIDEX (IRIX)
(Real Time Quote from BATS)
$2.07 USD
-0.05 (-2.36%)
Updated Jul 16, 2024 01:38 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IRIX 2.07 -0.05(-2.36%)
Will IRIX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IRIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRIX
Iridex (IRIX) Reports Q1 Loss, Misses Revenue Estimates
Lumentum (LITE) Q3 Earnings Beat Estimates
IRIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Iridex (IRIX) Reports Q4 Loss, Lags Revenue Estimates
Zacks Industry Outlook Highlights MicroVision, Cutera and IRIDEX
3 Laser Systems Stocks to Watch in a Challenging Industry
Other News for IRIX
Iridex Leadership and Governance Strengthened at Annual Meeting
IRIDEX Corporation (IRIX) Q1 2024 Earnings Call Transcript
Iridex on the Brink: Operational Losses and Funding Woes Threaten Company Viability
Analysts Offer Insights on Healthcare Companies: Iridex (IRIX), Nyxoah (NYXH) and Enliven Therapeutics (ELVN)
IRIDEX Corp (IRIX) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges with ...